Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan’s Drug Research Corp.

Executive Summary

Naproxen is lead compound in DRC's IPDAS gastrointestinal protective drug absorption system development program, Elan said Nov. 16 in announcement of completion of unit rights offering in DRC. Company hopes to show that IPDAS naproxen has a better side effect profile when dosed once-daily, along with less gastric irritation and side effects. Elan hopes to commence clinicals in "very near future" in order to have product on market in 1994. Rights offering for RDC was 50% oversubscribed. Unit offering raised $43.2 mil. to develop two early stage drug delivery systems ("The Pink Sheet" Sept. 3, p. 14). Elan said early work on ETDAS electrotransport "wristwatch" system will focus on cardiovascular and anti-asthma products and narcotic analgesics.
UsernamePublicRestriction

Register

PS018403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel